A Phase I Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years

Trial Profile

A Phase I Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Human papillomavirus 6/11 vaccine recombinant bivalent Xiamen (Primary)
  • Indications Condylomata acuminata
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jul 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016.
    • 13 Jul 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Sep 2016.
    • 30 Dec 2015 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top